0000000001285205
AUTHOR
Antonino Galuffo
showing 30 related works from this author
Intravesical gemcitabine in superficial bladder tumors. Results of a phase I-II study
2004
the good tolerability of intravesical gemcitabine have been recently published. The evaluation of the activity on a papillary marker lesion is the best tool to measure the efficacy of a drug by intravesical route against superficial transitional cell carcinoma of the bladder (TCCB). The scientific background and the ethical acceptability of this approach have been validated by the European Organization for Research and Treatment of Cancer Urological Group. The aim of the present study was to evaluate the ablative efficacy of weekly intravesical instillations of gemcitabine against a histologically proven papillary marker lesion. MATERIAL & METHODS: Twenty-seven patients, affected by recurre…
Ipertermia e chemioterapia nel tumore vescicale superficiale a medio rischio di recidiva:esperienza preliminare
2005
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica.
2005
FOLLOW UP A LUNGO TERMINE DI PAZIENTI CON POSITIVITA’ DELLA NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA
2005
TERAPIA DI II LINEA NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC) CON ESTRAMUSTINA FOSFATO ED ETOPOSIDE. STUDIO DI FASE II DEL GSTU
2005
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors
2004
INTRODUCTION AND OBJECTIVE: The possible role of gemcitabine inintravesical therapy of superficial transitional cell carcinoma of the bladder (TCCB) has been suggested. The European Organization for Research and Treatment of Cancer Urological Group validated the use of papillary marker lesion left in the bladder after TUR as the best tool to measure the efficacy of a drug by intravesical route against TCCB. The rsults on 27 patients are herein presented. METHODS: Twenty-seven patients, with recurrent superficial TCCB (Ta-T1, G1-G2), were treated with intravesical gemcitabine for 1 to 3 papillary marker lesions (5-15 mm) left unreseacted after TUR. Twenty-one patients (78%) had recurrent tum…
La terapia dei tumori vescicali superficiali: lo stato attuale
2005
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study
2004
-
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDO…
2006
-
Ruolo della terapia di mantenimento e fattori di rischio ambientale nel carcinoma vescicale superficiale. Pazienti sottoposti a chemioterapia endoves…
2005
Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU).
2005
PSA E PROSTATITE CRONICA CLINICAMENTE SILENTE IN PZ CON SOSPETTO CARCINOMA PROSTATICO T1C
2004
Risultati a lungo termine del trattamento con TUR e terapia endovescicale adiuvante nell’urotelioma vescicale T1G3. Recidiva, progressione e sopravvi…
2007
IS IT POSSIBLE TO PREDICT CHEMORESISTANCE OF SUPERFICIAL BLADDER CARCINOMA?
2004
Prostatite clinicamente silente (INH IV) ed elevazione del PSA.
2006
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO ED ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO. STUDIO RANDOMIZZAT…
2005
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3)
2004
LA RIDUZIONE DEL PSA DOPO TERAPIA ANTIBIOTICA NON HA VALORE PREDITTIVO IN SOGGETTI CANDIDATI ALLA AGOBIOPSIA PER SOSPETTO TUMORE PROSTATICO T1C
2005
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE?
2005
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder.
2006
OBJECTIVE: Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. METHODS: Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta-T1 G1-3 transitional cell carcinoma of the bladder. RESULTS: Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 38 (7%), spring water for 7 (1%) and mixed source for 89 (…
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre…
2005
Ipertermia e chemioterapia nel tumore vescicale superficiale a medio-alto rischio:esperienza preliminare sulla tollerabilità.
2004
low dose oral chemotherapy for hormone refractory prostate carcnoma.Estramustine phosphate versus estramustine phosphate and etoposide. A randomised …
2006
Role of antimicrobial tratment in patients with elevated PSA and normal digital rectal examination.
2006
Risultati di uno studio pilota di fase I-II con gemcitabina endovescicale nel tumore vescicale superficiale (TA-T1)
2005
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione –
2005
-